Fluvoxamine maleate

ApprovedSmall molecule

SSolvay Pharmaceuticals

Fluvoxamine maleate is one of 88 small molecule programs targeting Long COVID-19. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Long COVID-19Active, not recruiting

COVID-19Active, not recruiting

Obsessive-Compulsive DisorderActive, not recruiting

Long COVID-19Phase 3

Active, not recruiting

COVID-19Approved

Active, not recruiting

Obsessive-Compulsive DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Fluvoxamine maleate

SSolvay Pharmaceuticals

Approved

1 2

Biaxin

AbbVie

Preclinical

2 3

Aldactone

Pfizer

Preclinical

1 4

Singulair

AstraZeneca

Preclinical

1 5

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 9

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Obsessive-Compulsive Disorder2 trials

Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents

Terminated·SSolvay Pharmaceuticals·Phase 4·NCT00352768·20 enrolled

A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder

Completed· AbbVie logo

AbbVie·Phase 3·NCT01933919·38 enrolled

Adolescent1 trial

Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents

Completed·SSolvay Pharmaceuticals·Phase 4·NCT00353028·90 enrolled

COVID-191 trial

Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community

Completed·—·Phase 4·NCT05087381·1,200 enrolled

Long COVID-191 trial

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

Unknown status·CCardresearch·Phase 3·NCT06128967·1,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Fluvoxamine maleate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluvoxamine maleate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluvoxamine maleate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Solvay Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSolvay Pharmaceuticals

Fluvoxamine maleate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Obsessive-Compulsive Disorder2 trials

Adolescent1 trial

COVID-191 trial

Long COVID-191 trial

References

Drug Info

Quick Facts

Related News